Repositioning of Montelukast to inhibit proliferation of mutated KRAS pancreatic cancer through a novel mechanism that interfere the binding between KRAS and GTP/GDP
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Repositioning of Montelukast to inhibit proliferation of mutated KRAS pancreatic cancer through a novel mechanism that interfere the binding between KRAS and GTP/GDP
Authors
Keywords
-
Journal
European Journal of Pharmacology
Volume -, Issue -, Pages 176157
Publisher
Elsevier BV
Online
2023-11-07
DOI
10.1016/j.ejphar.2023.176157
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2023
- (2023) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Montelukast as a potential treatment for COVID-19
- (2023) Matthew W. McCarthy EXPERT OPINION ON PHARMACOTHERAPY
- Targeted therapies for KRAS-mutant non-small cell lung cancer: from preclinical studies to clinical development—a narrative review
- (2023) Mariacarmela Santarpia et al. Translational Lung Cancer Research
- Repositioning Lomitapide to block ZDHHC5-dependant palmitoylation on SSTR5 leads to anti-proliferation effect in preclinical pancreatic cancer models
- (2023) Yumeng Wang et al. Cell Death Discovery
- The path to the clinic: a comprehensive review on direct KRASG12C inhibitors
- (2022) Albert K. Kwan et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants
- (2022) Marco H. Hofmann et al. Cancer Discovery
- Targeting KRAS in Lung Cancer Beyond KRAS G12C Inhibitors: The Immune Regulatory Role of KRAS and Novel Therapeutic Strategies
- (2022) Marc Cucurull et al. Frontiers in Oncology
- KRAS: A Druggable Target in Colon Cancer Patients
- (2022) Francesca Negri et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Sotorasib: First approved KRAS mutation inhibitor for the treatment of non-small cell lung cancer
- (2022) Surya K. De CURRENT MEDICINAL CHEMISTRY
- Drugging KRAS: current perspectives and state-of-art review
- (2022) Kaushal Parikh et al. Journal of Hematology & Oncology
- Targeting KRAS in PDAC: A New Way to Cure It?
- (2022) Qianyu He et al. Cancers
- Leukotrienes vs. Montelukast—Activity, Metabolism, and Toxicity Hints for Repurposing
- (2022) Cátia F. Marques et al. Pharmaceuticals
- KRAS inhibitors: going noncovalent
- (2022) Matthias Drosten et al. Molecular Oncology
- KRAS G12D targeted therapies for pancreatic cancer: Has the fortress been conquered?
- (2022) Sahar F. Bannoura et al. Frontiers in Oncology
- Mechanisms of Resistance to KRASG12C Inhibitors
- (2021) Victoria Dunnett-Kane et al. Cancers
- KRAS mutation in pancreatic cancer
- (2021) Ji Luo SEMINARS IN ONCOLOGY
- Targeting KRAS in pancreatic cancer: new drugs on the horizon
- (2021) Sahar F. Bannoura et al. CANCER AND METASTASIS REVIEWS
- Sotorasib: First Approval
- (2021) Hannah A. Blair DRUGS
- Anti-Allergic Drug Suppressed Pancreatic Carcinogenesis via Down-Regulation of Cellular Proliferation
- (2021) Kenta Kachi et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Identification of MRTX1133, a Noncovalent, Potent, and Selective KRASG12D Inhibitor
- (2021) Xiaolun Wang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers
- (2021) Yuta Adachi et al. Cancers
- KRAS as a druggable target in NSCLC: Rising like a phoenix after decades of development failures
- (2020) Alex Friedlaender et al. CANCER TREATMENT REVIEWS
- Big data and artificial intelligence discover novel drugs targeting proteins without 3D structure and overcome the undruggable targets
- (2020) Huiqin He et al. JOURNAL OF INVESTIGATIVE MEDICINE
- KRAS: From undruggable to a druggable Cancer Target
- (2020) Dipesh Uprety et al. CANCER TREATMENT REVIEWS
- Structures of N-terminally processed KRAS provide insight into the role of N-acetylation
- (2019) Srisathiyanarayanan Dharmaiah et al. Scientific Reports
- Predictive signatures inform the effective repurposing of Decitabine to treat K-RAS-dependent Pancreatic Ductal Adenocarcinoma
- (2019) Carla Mottini et al. CANCER RESEARCH
- The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
- (2019) Jude Canon et al. NATURE
- Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer
- (2019) G. Aaron Hobbs et al. Cancer Discovery
- Artificial intelligence and big data facilitated targeted drug discovery
- (2019) Benquan Liu et al. JOURNAL OF INVESTIGATIVE MEDICINE
- Montelukast inhibits hypoxia inducible factor-1α translation in prostate cancer cells
- (2018) Caixia Tang et al. CANCER BIOLOGY & THERAPY
- Montelukast Induces Apoptosis-Inducing Factor-Mediated Cell Death of Lung Cancer Cells
- (2017) Ming-Ju Tsai et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- A Comprehensive Survey of Ras Mutations in Cancer
- (2012) I. A. Prior et al. CANCER RESEARCH
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started